 Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate 3.9 billion. The post NVAX Stock Is Worth a Small Position but Vaccine Race Is Tightening appeared first on InvestorPlace. 